Correlation between pretherapeutic D-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer

Diseases of the Esophagus

Volumn 21, Issue 4, 2008, Pages 281-287

  Tomimaru, Y ^a   Yano, Masahiko ^a   Takachi, K ^a   Kishi, K ^a   Miyashiro, I ^a   Ohue, M ^a   Ohigashi, H ^a   Sasaki, Y ^a   Ishikawa, O ^a   Imaoka, S ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

D dimer; Esophageal cancer; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; D DIMER; DOXORUBICIN; FLUOROURACIL;

ACCURACY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; FEMALE; HUMAN; HYPERCOAGULABILITY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 43449131573     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00758.x     Document Type: Article

References (36)

1. Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T, Okudaira Y. Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet 1983; 157: 537-40.
2. Ajani J A, Roth J A, Ryan B et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990; 8: 1231-8.
3. Yano M, Inoue M, Shiozaki H. Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer. Ann Thorac Cardiovasc Surg 2002; 8: 123-30.
4. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-33.
5. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-7.
6. Duhaylongsod F G, Gottfried M R, Iglehart J D, Vaughn A L, Wolfe W G. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995; 221: 677-83.
7. Hickey K, Grehan D, Reid I M, O'Briain S, Walsh T N, Hennessy T P. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994; 74: 1693-8.
8. Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann E H, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002; 21: 657-63.
9. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002; 89: 597-603.
10. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris, 3rd edn. Paris: J-B. Balliere et Fils, 1865; 654-712.
11. Rickles F R, Edwards R L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
12. Bick R L. Coagulation abnormalities in malignancy: A review. Semin Thromb Hemost 1992; 18: 353-72.
13. Kakkar A K, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson R C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5.
14. Forster Y, Meye A, Albrecht S, Schwenzer B. Tissue factor and tumor: clinical and laboratory aspects. Clin Chim Acta 2006; 364: 12-21.
15. Yu J L, May L, Klement P, Weitz J I, Rak J. Oncogenes as regulators of tissue factor expression in cancer: Implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004; 30: 21-30.
16. Ma L, Francia G, Viloria-Petit A et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: Modulation by lower-dose chemotherapy. Cancer Res 2005; 65: 5365-73.
17. Tomimaru Y, Yano M, Takachi K et al. Plasma d -dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-45.
18. Blackwell K, Hurwitz H, Lieberman G et al. Circulating d-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101: 77-82.
19. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17: 667-73.
20. Gabazza E C, Taguchi O, Yamakami T et al. Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer. Eur J Cancer 1994; 30: 1276-81.
21. Rella C, Coviello M, De Frenza N et al. Plasma d-dimer measurement as a marker of gynecologic tumors: Comparison with Ca 125. Tumori 1993; 79: 347-51.
22. Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 1995; 55: 4881-5.
23. Lebeau B, Chastang C, Brechot J M et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45.
24. Kakkar A K, Levine M N, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8.
25. Altinbas M, Coskun H S, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-71.
26. Klerk C P, Smorenburg S M, Otten H M et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5.
27. Beahrs O H, Henson D E, Hutter R V, Kennedy B J, (eds). American Joint Committee on Cancer: Manual of Staging of Cancer, 4th edn. Philadelphia: JB Lippincott, Inc. 1993, 75-9.
28. Yano M, Takachi K, Doki Y et al. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2006; 19: 158-63.
29. Antoniou D, Pavlakou G, Stathopoulos G P et al. Predictive value of d-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 2006; 53: 205-10.
30. Weber W A, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
31. Westerterp M, Omloo J M, Sloof G W et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia 2006; 22: 149-60.
32. Foekens J A, Peters H A, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-14.
33. Dirix L Y, Vermeulen P B, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-43.
34. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79: 144-6.
35. Hyodo I, Doi T, Endo H et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34: 2041-5.
36. Jiang X, Guo Y L, Bromberg M E. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006; 96: 196-201.